Next Article in Journal
Compartmental and COMSOL Multiphysics 3D Modeling of Drug Diffusion to the Vitreous Following the Administration of a Sustained-Release Drug Delivery System
Next Article in Special Issue
Transcutaneous Administration of Imiquimod Promotes T and B Cell Differentiation into Effector Cells or Plasma Cells
Previous Article in Journal
Utilization of Pharmaceutical Technology Methods for the Development of Innovative Porous Metasilicate Pellets with a Very High Specific Surface Area for Chemical Warfare Agents Detection
Previous Article in Special Issue
An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 13
Issue 11
10.3390/pharmaceutics13111859
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants

by
Yunys Pérez-Betancourt
1,
Péricles Marques Araujo
1,
Bianca de Carvalho Lins Fernandes Távora
2,3,
Daniele Rodrigues Pereira
2,3,
Eliana Lima Faquim-Mauro
2,3 and
Ana Maria Carmona-Ribeiro
1,*
1
Biocolloids Laboratory, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Avenida Professor Lineu Prestes, 748 Butantan, São Paulo 05508-000, Brazil
2
Immunopathology Laboratory, Butantan Institute, Avenida Vital Brasil, 1500 Butantan, São Paulo 05503-900, Brazil
3
Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, Avenida Professor Lineu Prestes, 1730 Butantan, São Paulo 05508-000, Brazil
*
Author to whom correspondence should be addressed.
Pharmaceutics 2021, 13(11), 1859; https://doi.org/10.3390/pharmaceutics13111859
Submission received: 27 September 2021 / Revised: 1 November 2021 / Accepted: 3 November 2021 / Published: 4 November 2021
(This article belongs to the Special Issue Discovery and Evaluation of Novel Adjuvants for Vaccine Formulations)
Browse Figures
Versions Notes

Abstract

:
Nanostructures have been of paramount importance for developing immunoadjuvants. They must be cationic and non-cytotoxic, easily assembling with usually oppositely charged antigens such as proteins, haptens or nucleic acids for use in vaccines. We obtained optimal hybrid nanoparticles (NPs) from the biocompatible polymer poly(methyl methacrylate) (PMMA) and the cationic lipid dioctadecyl dimethyl ammonium bromide (DODAB) by emulsion polymerization of methyl methacrylate (MMA) in the presence of DODAB. NPs adsorbed ovalbumin (OVA) as a model antigen and we determined their adjuvant properties. Interestingly, they elicited high double immune responses of the cellular and humoral types overcoming the poor biocompatibility of DODAB-based adjuvants of the bilayer type. The results suggested that the novel adjuvant would be possibly of use in a variety of vaccines.

1. Introduction

In vaccine design, cationic nanostructures are very important as adjuvants for carrying antigens. Their nanometric size avoids retention by physiological barriers at the site of injection allowing them to reach lymph nodes and dendritic cells more easily [1,2,3,4,5,6]. They can be obtained from a variety of lipids, polymers or lipids and polymers, mostly as bilayer vesicles [7,8], open bilayer disks [9,10,11,12,13], lipid nanoparticles [14] or hybrid nanoparticles [15,16,17,18,19,20,21].
In particular, the cationic and synthetic lipid dioctadecyl dimethyl ammonium bromide (DODAB) self-assembles both as closed and large bilayer vesicles [8,22] or as open and cationic bilayer fragments or nanodisks (DODAB BF) with sizes below 100 nm that fuse upon relaxation of the surface potential due to the addition of monovalent salt [23]. DODAB bilayers can combine with a broad variety of antigens or enhancers of the immune response, such as proteins [7,10,24,25], peptides [18,26,27], oligonucleotides [11,28], mononucleotides [29,30] or nucleic acids [31,32], driving an enhanced cell-mediated immune response, but a poor humoral response in several instances [7,10,11,15].
The versatile character of the DODAB molecules and their assemblies directed our research to characterize the many DODAB interactions with oppositely charged particles such as polystyrene sulfate latexes [15,18,33,34,35] or silica [36,37,38,39]. This basic knowledge led to the optimized deposition of supported DODAB bilayers on polystyrene sulfate (PSS) nanoparticles [15,18,35] or silica [38,39] as suitable immunoadjuvants and antigen carriers. The preparation and characterization of PSS/DODAB NPs, where a single DODAB bilayer surrounds each PSS NP was described [18].
The good miscibility of DODAB with the biocompatible polymer poly(methylmethacrylate) (PMMA) [16,40] motivated the preparation of hybrid PMMA/DODAB NPs by emulsion polymerization of methylmethacrylate (MMA) in the presence of DODAB. These hybrid, cationic and nanometric PMMA/DODAB NPs were described previously [19]. Here we test the application of these PMMA/DODAB NPs as immuno-adjuvants carrying ovalbumin (OVA) as a model antigen. The advantages of the PMMA/DODAB NPs were biocompatibility, high affinity for oppositely charged antigens and induction of a mixed Th2/Th1 immune response.

2. Materials and Methods

2.1. Materials

MMA, azobisisobutyronitrile (AIBN), NaCl, DODAB, chloroform, grade V ovalbumin, ortho-phenilenediamine dihydrochloride (OPD), peroxidase—labeled streptavidin, and concanavalin A—were purchased from Sigma-Aldrich (Saint Louis, MO, USA). OVA stock solution was prepared in Milli-Q water at 15 mg/mL and was purified by chromatography (polymyxin B columns; Pierce Biotechnology, Rockford, IL, USA), analyzed by the bicinchoninic acid (BCA) assay, and adjusted to 10 mg/mL. Al(OH)3 as adjuvant was purchased from Sanofi—Synthelabo, RJ, Brazil. Cellulose acetate membranes (12,400 g/mol molecular weight cut off) were used for dialyzing the nanoparticles dispersions. Analytical grade reagents were used throughout without purification.
The chemical structures for MMA, DODAB and PMMA are presented in Scheme 1.

2.2. Spreading of DODAB Films, Preparation of DODAB Bilayer Fragments (DODAB BF) and Synthesis of PMMA/DODAB NPs

Two different DODAB dispersions in water solution were prepared: (1) dispersions from DODAB films [27,41]; (2) DODAB bilayer fragments (BF) [8,9,42]. DODAB films on the bottom of glass tubes were obtained from a 10 mM DODAB solution in chloroform submitted to evaporation under nitrogen flow. For preparing DODAB BF, DODAB powder was sonicated for 15 min in 1 mM NaCl water solution using a macroprobe (85 W) and then centrifuged for pelleting titanium ejected from the tip (9300× g/1 h/4 °C).
The synthesis of PMMA/DODAB NPs was carried out by polymerizing MMA (emulsion polymerization) in the presence of DODAB and AIBN initiator [16,19,43]. In the tubes containing the dry DODAB films or DODAB bilayer fragments (BF), MMA (0.1 to 0.56 M), 0.036 g AIBN and 1 mM NaCl solution were added to a final volume of 10 mL and placed in a water bath at 70–80 °C for 1 h with periodic vortexing before exhaustive dialysis for eliminating unreacted monomer (4 L water, 6 times change, 72 h/Milli-Q water).

2.3. Determining Physical Properties of NPs by Dynamic Light-Scattering (DLS)

Dispersions were diluted 20 times for zeta-average diameter (Dz), zeta-potential (ζ) and polydispersity (P) DLS measurements using a Zeta-Plus Zeta-Potential Analyzer (Brookhaven Instruments Corporation, Holtsville, NY, USA), which was equipped with a 677 nm laser and dynamic light-scattering (DLS) at 90° for particle sizing. From fluctuations of scattered light intensity, the decay times of the fluctuations can be related to the diffusion constants and, therefore, to the sizes of the particles. Small particles moving rapidly cause faster decaying fluctuations than large particles moving slowly. The decay times of these fluctuations are determined in the time domain using a correlator. The fluctuating signal is processed by forming the autocorrelation function which decays exponentially with time so that the relaxation of the fluctuations is directly related to the decay constant (Γ). The decay constant is given by Equation (1):
Γ = Dq2
where q depends on the scattering angle, the wavelength of the laser light and refractive index of the suspending liquid and D is the translational diffusion coefficient.
Hydrodynamic particle diameter (Dz) is inversely related to D by the Stokes-Einstein Equation (2):
Dz = kT/(3πηD)
where k is the Boltzmann’s constant, T is temperature in Kelvin, η is the viscosity of the suspending liquid, and D is the diffusion coefficient. Mean diameters were obtained by fitting data to log-normal size distributions that do not discriminate between one, two, or more different populations and always consider all scattering particles as belonging to one single Gaussian population. For the size distribution data, fitting was performed by the apparatus software using the non-negatively constrained least-squares (NNLS) algorithm, which is a model-independent technique allowing multimodal distributions to be achieved [44].
In order to define a relative width of size distributions, the polydispersity P is given by Equation (3):
P = µ2Γ2
where μ2 is proportional to the variance of the “intensity” weighted diffusion coefficient distribution and carries information on the width of the size distribution. Polydispersity (P) has no units. It is close to zero (0.000 to 0.020) for monodisperse or nearly monodisperse samples, small (0.020 to 0.080) for narrow distributions and larger for broader distributions. ζ was determined from electrophoretic mobility (µ) in 1 mM NaCl and the Smoluchowski equation (Equation (4)):
ζ = μη/ε
where η is the medium viscosity and ε the medium dielectric constant. DODAB differs from surfactants by being a lipid.

2.4. Determination of Solid Content and DODAB Concentration in NPs

Solid contents (mg/mL) in the dispersions were quantified by weighing 1 mL NPs dispersions before and after lyophilization as previously described [16,17,19,45]. Centrifuging dispersions (1 h/10,000 rpm) and pelleting NPs allowed the determination of DODAB concentration in the supernatant from halide microtitration [46]. DODAB concentration in NPs was obtained by subtracting DODAB concentration in the supernatant from DODAB concentration used for NPs synthesis [21,45].

2.5. Determination of Interaction of PMMA/DODAB NPs (20 mg/mL PMMA and 1.6 mM DODAB) and OVA

After washing out DODAB in the supernatant of a PMMA/DODAB NPs dispersion by centrifuging and re-suspending the initial dispersion three times in pure water, an aliquot containing 0.50 mg/mL PMMA and 0.08 mM DODAB interacted with OVA over a range of OVA concentrations during 1 h interaction time. Thereafter, photos, DLS measurements and determination of OVA adsorption onto NPs from OVA analysis in the supernatants of the NPs/OVA mixtures were obtained [47]. Adsorbed [OVA] was obtained after centrifuging (10,000 rpm/1 h/25 °C) by subtracting OVA concentration in the supernatant from the OVA concentration added.

2.6. Determination of Cell Viability in the Presence of PMMA/DODAB NPs as Compared to the One with DODAB Vesicles and Bilayer Fragments

Three DODAB adjuvants were tested against cells in culture: PMMA/DODAB NPs, DODAB bilayer vesicles (DODAB LV) and DODAB BF. Stock dispersions of the three adjuvants were: (1) PMMA/DODAB NPs at 20 mg/mL PMMA and 1.6 mM DODAB; (2) DODAB LV at 10 mM DODAB in DODAB dispersions obtained by vortexing the DODAB powder in 1 mM NaCl solution above 47 °C [41]; (3) DODAB BF at 10 mM DODAB obtained by sonication in 1 mM NaCl with a macro-probe. Aliquots of each stock dispersion of adjuvants were mixed with cells’ culture media over a range of DODAB concentrations (0.04, 0.08, 0.12, 0.16 mM DODAB for each adjuvant type). Thereafter 0.1 mL of each adjuvant type and concentration in culture medium were added to subconfluent layers of L929 fibroblasts or J774A.1 macrophages (American Type Culture Collection).
Cell lines were cultured according to standard protocols (90% humidity, 5% CO2, 37 °C), RPMI—1640, 5% fetal bovine serum (FBS), 1% penicillin—streptomycin, 2 mM L—glutamine, and 0.25% 2—mercaptoethanol. In a humidified CO2 incubator, 0.1 mL of DODAB-containing adjuvant previously diluted in the cells medium (0.1 mL) interacted with plated cells (10,000 cells/well) for 3 and 24 h. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay evaluated cytotoxicity. Ten microliters of MTT solution in PBS (5 mg/mL MTT) was added per well. This stock MTT solution was previously filtered for sterilization and removal of insoluble residues. After incubation (37 °C/2 h), supernatant withdrawing, and mixing of adhered cells with 100 µL isopropanol solution in 0.04 N HCl, the absorbance at 570 nm was determined on an ELISA reader. One hundred percent of cell viability was given by cells in the culture medium only.

2.7. Immunization Protocol

Animals were immunized subcutaneously according to four groups with five BALB/c male mice each. They were injected with 0.1 mL of solution or dispersion on the base of the tail at two separate sites with 0.1 mL each (0.2 mL per animal in total). The composition of solutions or dispersions used for immunization is in Table 1. Animals received a booster with the same priming dose on day 21 after immunization.

2.8. OVA-Specific IgG1 and IgG2a Production by ELISA in Immunized Mice

Animals’ blood was collected from the ophthalmic plexus at days 14, 21 and 28 postimmunization for serum individual analysis by indirect enzyme-linked immunosorbent assay (ELISA). Microtiter plates (Costar Corning Inc., Kennebunk, ME, USA) were incubated overnight at 4 °C with 0.1 mL OVA solution at 0.010 mg/mL in 0.01 M PBS, pH 7.2. Gelatin 3% in PBS blocked the wells for 2 h before adding serially diluted serum and further incubating the microplates for 1 h at 37 °C. 0.100 mL of goat anti-mouse biotin-conjugated IgG1 (1:1000) or IgG2a (1:500) (Southern Biotechnology Associates, Birmingham, AL, USA) were added per well for incubation (1 h/37 °C). Thereafter, peroxidase-labeled streptavidin (0.100 mL/diluted 1:3000) was added and incubated for 1 h at 37 °C. Three-times washing was performed after each incubation step with PBS containing 0.05% Tween 20 (PBST). An amount of 0.1 mL of ortho-phenilenediamine dihydrochloride (OPD) substrate solution at 1 mg/mL and H2O2 (1 μL/mL) in 0.1 M citrate-phosphate at pH 5.0) were added per well for 15 min incubation at 25 °C. An amount of 0.050 mL of a H2SO4 solution (2 M) terminated the reaction. Optical density at 492 nm was read in an ELISA apparatus (Multiskan Ex, Thermo Electron Corporation, Waltham, MA, USA). Samples were diluted to fit inside the 0–1 absorbance range and data were shown. The results were expressed for diluted serum samples as the mean values ± standard deviation. For IgG1 dilution of 1:1024 corresponded to the primary response and 1/512,000, to the secondary one. For IgG2a, primary and secondary responses were present at 1:32 and 1:512 dilutions.

2.9. Determination of Delayed-Type Hypersensitivity Reaction (DTH)

DTH associated with cell-mediated immune response was evaluated from footpad swelling in mice [7,11,38,48]. At day 5 postimmunization, mice received injections of denaturated OVA in saline solution (0.030 mL of a 2 mg/mL OVA) at the left-hind footpad. Negative control was 0.030 mL of saline injected at the right-hind footpad of each animal. Footpad swelling at 24 h after injection was measured with a Mitutoyo digital micrometer. The difference between swelling of left and right hind footpads of a given 24 h after injection was taken as the individual footpad swelling. The mean footpad swelling ± standard deviation could be calculated considering all five animals in each group.

2.10. Determination of Cytokines Profile from Cultured Spleen Cells

Two weeks after the booster, spleen cells from spleens of five immunized mice of the same group were cultured in RPMI 1640 medium with 2 mM L—glutamine, 5% FBS and 0.25% 2-mercaptoethanol [21,49]. Suspensions (8 × 106 cells/mL) distributed in tissue culture plates were incubated with medium containing 250 μg/mL OVA in a humidified CO2 incubator for 72 h. Negative and positive controls were medium only or 2.5 μg/mL concanavalin A (Con-A), respectively. Thereafter, plates were centrifuged (5 min/1500 rpm) and the supernatants collected for determining IL-2, IL-4, IL-10 and IFN-γ (sandwich ELISA kit, catalog number #88-7711-44, Thermo Fisher Scientific, Waltham, MA, USA). Detection limits were 30 (IL-10), 2 (IL-2), 4 (IL-4) and 15 pg/mL (IFN-γ); cytokine concentrations were expressed as mean of duplicate assays ± mean standard deviation.

2.11. Statistics Tests

The significance of results for different groups was evaluated using a two-way ANOVA variance analysis and the multiple comparisons Tukey’s test. p < 0.05 meant significant differences between results. The software for statistical analysis was provided by the Origin 2018 program available from the Origin Lab Corporation, Northampton, MA, USA.

3. Results and Discussion

3.1. Synthesis of Nanoparticles (NP), NPs Physical Properties and Cytotoxicity against Cultured Cells

The background for synthesizing PMMA/DODAB NPs has been the high miscibility of DODAB and PMMA due to weak but numerous intermolecular interactions [40]. The hybrid coatings using PMMA/DODAB materials joined the high biocompatibility of PMMA [21,50,51] with the antimicrobial activity of the quaternary ammonium moiety of DODAB [52,53,54,55]. Here we take advantage of PMMA biocompatibility and DODAB activity as immunoadjuvant to obtain hybrid NPs of PMMA/DODAB. One should also recall the high surface potential of DODAB nanostructures, bilayer fragments and bilayer vesicles [56] favoring the adsorption of oppositely charged antigens, an essential property for combining antigen and adjuvant. The main physical properties of PMMA/DODAB NPs obtained by emulsion polymerization of MMA in the presence of DODAB were on Figure 1.
Figure 1 showed the effect of MMA or DODAB concentration used during NPs synthesis on physical properties of PMMA/DODAB NPs. DODAB BF or DODAB dispersed as films on the bottom of the glass tube when used in the MMA polymerization medium yielded polymeric NPs further characterized by DLS for sizing, polydispersity (P) and zeta-potentials (ζ). Sizes (Dz) (Figure 1a), zeta-potentials (ζ) (Figure 1b) and polydispersities (P) (Figure 1c) were shown over a range of PMMA or DODAB concentrations. Nanometric size (50–80 nm) was mainly achieved using the DODAB BF during NPs synthesis over a range of MMA concentrations (Figure 1a). DODAB BF emulsified MMA better than DODAB films casted on the bottom of glass tubes. Therefore, in Figure 1a,d, NPs synthesized in the presence of DODAB BF (red points) were always smaller than those synthesized in the presence of DODAB films (blue points).
Over a range of low [MMA] (below 0.2 M MMA) in the reaction mixture, dispersions contained polydisperse NPs in contrast to the narrow size distribution obtained above 0.2 M MMA (Figure 1c). Thus [MMA] concentrations for nanometric sizes, high zeta-potential and narrow size distribution should be chosen above 0.2 M (concentration chosen was 0.3 M). Regarding the use of DODAB films for NPs synthesis, no signicant difference in zeta-potential and polydispersity was observed, but sizes tended to be always larger than the ones for NPs obtained from DODAB BF (Figure 1a–c).
At 0.3 M MMA, BFs confirmed their suitability to yield NPs sizes below 100 nm; DODAB films yielded always larger NPs (Figure 1d). This had already been observed on Figure 1a, where films yielded always larger NPs than those prepared in the presence of DODAB BF. Again, nanometric size (50–80 nm) was mainly achieved using the DODAB BF during NPs synthesis over a range of MMA concentrations (Figure 1d). DODAB BF emulsified MMA better than DODAB films casted on the bottom of glass tubes. Possibly, DODAB BF present in the aqueous reaction medium organized the growing chains of PMMA in the core of the bilayer fragments at early stages of the polymerization. The high miscibility between PMMA and DODAB led to hybrid NPs where DODAB could be localized both in the polymer matrix and on the NP surface. Curiously, DODAB affinity for PMMA has been shown to be higher than the one for cetyltrimethylammonium bromide (CTAB): whereas DODAB remains in the polymer matrix, CTAB diffuses through the polymer network reaching the outer water medium [19,40,57].
Figure 1e,f confirmed similar zeta-potentials and polydispersities for NPs synthesized in the presence of DODAB BF or DODAB films.
Figure 2a showed the DODAB incorporation at 1.5 mM DODAB onto PMMA/DODAB NPs over a range of [MMA]. DODAB incorporation in the PMMA/DODAB NPs increased with [MMA] over a low range of [MMA] (0–0.3 M MMA). Above this range, further increasing [MMA] did not increase DODAB incorporation in the NPs.
From a certain MMA concentration it was not possible to disperse all PMMA as NPs due to lack of DODAB emulsifier; polymerization proceeded anyway yielding precipitated polymeric masses in the reaction mixtures; this occurred mainly over a range of [MMA] above 0.3 M (Figure 2a). Thus there is a need of establishing the saturation of PMMA with DODAB at a given concentration of MMA. For example, until 0.3 M MMA there was a linear dependence of DODAB incorporation from BF into PMMA/DODAB NPs (Figure 2a). However, it was observed that above 0.3 M MMA there were nonemulsified, precipitated polymer masses at the bottom of the assay tubes after NPs synthesis. For DODAB from films, the emulsification was even more hampered due to a lower availability of DODAB molecules to diffuse into the reaction mixture; at least for BF, the previous step of dispersing DODAB by sonication placed DODAB in a more suitable position as emulsifier for obtaining well dispersed polymeric NPs (Figure 2a,b). DODAB incorporation in NPs was always higher for polymerizations in the presence of BF than those in the presence of films (Figure 2). Furthermore, from DODAB added as BF, at 0.3 M MMA, there was a linear dependence of DODAB incorporation with the total DODAB concentration added to the reaction mixture, at least up to 1.5 mM DODAB (Figure 2b). In addition, all DODAB added could become incorporated in the NPs (Figure 2b). Above 1.5 mM DODAB added not all DODAB became part of the NPs meaning that the maximal DODAB incorporation had been achieved at a certain proportion of MMA/DODAB, namely 0.3 M MMA and 1.5 mM DODAB (Figure 2b).
The initial study determining the optimal molar ratio for MMA/DODAB during polymerization, namely 0.3:0.0015 MMA:DODAB, suggested this ratio for synthesizing the NPs to be evaluated as antigen presenters. The concentrations used for NPs synthesis in the next experiments were 0.3 M MMA and 0.0020 M DODAB, considering that the cationic DODAB usually adsorbs onto all glass [58] or plastic containers [33]. In other words, we synthesized the NPs under a slight excess of DODAB, even though complete removal of DODAB by centrifuging, discarding the supernatant and resuspending in pure water was routinely done. For the final NPs, [DODAB]p was 1.62 mM.
In the presence of PMMA/DODAB NPs, DODAB BF and DODAB LV, determination of the viability of macrophages or fibroblasts in culture pointed out that DODAB concentration at 0.08 mM barely affected the macrophages and the fibroblasts after a period of 24 h interaction (Figure 3). In contrast with DODAB BF or DODAB LV, the PMMA/DODAB NPs resulted much less cytotoxic against the macrophages (Figure 3b). The [DODAB] selected to the next experiments on adjuvant activity of the NPs was selected as 0.08 mM DODAB.
One should notice that from a NPs dispersion of 20 mg/mL PMMA (determined from solid contents of the PMMA/DODAB dispersion) synthesized in the presence of 2.0 mM DODAB, after centrifuging to precipitate the NPs and determining the DODAB concentration in the supernatant as 0.38 mM the [DODAB]p would be 1.62 mM. From this dispersion with 20 mg/mL PMMA and 1.62 mM DODAB, aliquots were taken to yield the four final [DODAB] on Figure 3, namely, 0.04, 0.08, 0.12 and 0.16 mM DODAB; for PMMA, final concentrations were 0.25, 0.50, 0.75 and 1.00 mg/mL, respectively. Curiously, there was no cytotoxicity against the fibroblasts in the presence of all three adjuvants over the 0–0.16 mM range of [DODAB] (Figure 3c,d). This result agrees with previous data on fibroblasts cell death in the presence of DODAB BF showing significant DODAB cytotoxicity only above 0.5 mM DODAB [59]. In summary, the use of DODAB mixed as a hybrid material with a biocompatible polymer such as PMMA advantageously reduced DODAB toxicity against the macrophages.

3.2. Ovalbumin Adsorption onto NPs, NPs/OVA Physical Properties and Colloidal Stability, and NPs/FITC-OVA Internalization in Macrophages

OVA adsorption onto PMMA/DODAB NPs was determined at 0.5 mg/mL PMMA over a range of added OVA concentrations. The reason for choosing this PMMA concentration was the possibility of comparing later on, the adjuvant effects of PMMA/DODAB with the previously described effects for PMMA/DODAB/PDDA NPs as adjuvants at this same concentration [21].
The oppositely charged OVA adsorbed onto PMMA/DODAB NPs at 0.5 mg/mL PMMA over a range of [OVA] yielding the macroscopic features shown on Figure 4a. Upon charge neutralization and zeta-potentials around zero, there was precipitation and loss of colloidal stability around 0.100–0.125 mg/mL of OVA (Figure 4a,d).
This behavior is usually obtained for interaction between NPs and oppositely charged molecules such as silica/DODAB [37], and polystyrene sulfate NPs/DODAB [15,33]. Around neutralization, large aggregates precipitate and polydispersity increases substantially; basically, it is not possible to use the DLS technique due to the absence of colloids in dispersion. The determination of colloidal stability was important to define OVA concentration to be combined with 0.5 mg/mL PMMA. To obtain positively charged NPs, their concentrations should be smaller than 0.1 mg/mL; furthermore, at 0.1 mg/mL OVA, aggregation and precipitation hampered the use of this OVA concentration. The OVA concentration chosen was 0.05 mg/mL in combination with 0.5 mg/mL PMMA/DODAB NPs. The reason for choosing 0.5 mg/mL PMMA/DODAB NPs was to compare later on the adjuvant effect with the one induced by PMMA/DODAB/PDDA NPs described previously at this same concentration [21].
The red point on Figure 4c–e showing the physical properties of NPs/OVA were obtained from a 1 mg/mL OVA stock solution. As compared to NPs/OVA obtained from a 10 mg/mL OVA stock solution (black points), sizes and polydispersities were smaller for the NPs obtained from the 1 mg/mL OVA. This was observed previously for concentrated OVA stock solutions and attributed to OVA-OVA interactions leading to OVA aggregation in the stock solution that remains to a certain extent after further dilution [60]. Thus, the stock OVA solution used was the one at 1 mg/mL OVA (red points in Figure 4c–e).
The OVA adsorption onto PMMA/DODAB NPs at 0.5 mg/mL PMMA increased linearly with added OVA concentration up to 0.1 mg/mL of added OVA (Figure 4b). Above this concentration NPs became saturated with OVA and further adsorption was substantially reduced. Therefore, 0.05 mg/mL of added OVA was suitable to ensure that all OVA added was adsorbed onto the NPs, no free OVA remained in solution.
In comparison with PMMA/DODAB/PDDA NPs (zeta-potentials around 70 mV), the present system with PMMA/DODAB NPs exhibited smaller zeta-potentials (around 30 mV) but maximal OVA adsorption was similarly around 0.10–0.12 mg/mL for both systems [21]. This can be better understood from the compared sizes for both NPs. PMMA/DODAB/PDDA NPs (Dz = 217 nm) were larger than PMMA/DODAB NPs (Dz = 81 nm). At 0.5 mg/mL PMMA for both NPs, the total surface area available for OVA adsorption is larger for the smaller NPs explaining why the lower zeta-potential resulted in similar adsorption to the one obtained with the PMMA/DODAB/PDDA NPs with higher zeta-potential. Small sizes compensated for the lower zeta-potentials.

3.3. Immune Response of NPs/OVA In Vivo: Improved Production of IgG1 and IgG2a

IgG1 and IgG2a OVA-specific antibodies production was enhanced substantially using NPs/OVA for immunization (Figure 5). Furthermore, NPs were as efficient as Al(OH)3 as adjuvants inducing the IgG1 primary response on days 14 and 21 but surpassed alum regarding the secondary response on day 28 (Figure 5a). IgG2a production induced by NPs/OVA was substantially superior to the one induced by alum both for the primary and the secondary response, suggesting and important role of the novel NPs in promoting cellular immune response (Figure 5b). Similar NPs made of the biocompatible PMMA and a cationic polymer were previously used as adjuvants also yielding improved humoral response [21,43]. Emulsion polymerization of methyl methacrylate (MMA), producing poly(methyl methacrylate) (PMMA), is well described in the literature [61,62,63]. We have been studying the effect of adding cationic lipid, surfactant or polymer to obtain cationic PMMA NPs useful as immunoadjuvants. Adding a cationic polymer to obtain PMMA/cationic polymer NPs, the IgG1 production was about four times higher than the one induced by alum [21] whereas in the present work, adding the cationic lipid DODAB to obtain PMMA/cationic lipid NPs, the IgG1 production was similar to the one induced by alum (Figure 5a). Production of IgG2a induced by PMMA/cationic lipid (Figure 5b) was four times higher than the one induced by PMMA/cationic polymer [21]. The cationic polymer PDDA was shown to enhance humoral response at levels superior to those attributed to polyethyleneimine (PEI) or cetyltrimethylammonium bromide (CTAB) adsorbed to gold nanorods [64].
In order to obtain more quantitative data on IgG1 and IgG2a antibodies production, the endpoint titers were obtained in both cases and shown on Table 2. The qualitative data described on Figure 5 were reconfirmed by the titers’ determination. PMMA/DODAB NPs induced indeed a mixed Th1-Th2 response in contrast to OVA alone or alum as adjuvant. Although OVA alone induced a certain production of IgG1, the production of IgG2a was basically neglectable (Table 2).
In summary, the NP structure determines the magnitude of both humoral and cellular responses when used as adjuvants. The cationic component as the outermost layer imparts high surface potential to the NPs and is seen by the immune system as a foreign body. The hybrid cationic lipid/PMMA NPs exhibit a lower surface potential due to uniform distribution of the cationic lipid in the polymer matrix and are not seen as so foreigner by the immune system.
Figure 6 shows the footpad swelling (FS) in mm for PMMA/DODAB NPs as compared to alum. The FS was 0.7 mm (Figure 6) and lower than the one previously determined for DODAB BF/OVA by Rozenfeld and coworkers, which was 1.3 mm [11]. Whereas the zeta-potential for PMMA/DODAB/OVA in this work is about 34 mV (Figure 4d), the zeta-potential for DODAB BF/OVA was determined as 21 mV [11]. The less charged nanostructure apparently induced the larger cellular response.
Some cytokines elicited by medium (negative control), OVA or concanavalin-A in cultured spleen cells of animals previously immunized with water (naive), OVA, Al(OH)3/OVA or PMMA/DODAB/OVA NPs allowed to reconfirm the intensity of humoral and cellular immune responses (Figure 7). Whereas IL-4 enhancement means improved humoral response (Figure 7a) and IL-10 enhancement relates to both humoral and cellular responses (Figure 7b), IL-2 (Figure 7c) and IFN-γ are typically produced in enhanced cellular immune response (Figure 7d). This profile perfectly agrees with previous results reported in this work where significant enhancements in both cellular (Figure 5b and Figure 6) and humoral immune responses were indeed described (Figure 5a). IL-10 enhancement means a regulatory response against the pro-inflammatory effect of NPs/OVA in mice.
In the presence of DODAB and poly(diallyl dimethylammonium chloride) (PDDA), emulsion polymerization of MMA yielded PMMA/DODAB/PDDA NPs [21,43,45]. These hybrid, PMMA-based NPs predominantly contained PMMA, a biocompatible polymer, displaying absence of cytotoxicity when tiny amounts of cationic components were used, as shown in this work. The comparison between PMMA/DODAB NPs (this work) and PMMA/DODAB/PDDA [21] showed some differences in the type of immune response. The former NPs induced preferentially a Th-1 response (higher IgG2a, IFN-γ and lower IL-10 for down regulation of inflammatory response induced by the PMMA/DODAB NP) as compared to the PMMA/DODAB/PDDA NPs that generated higher Th-2 response (lower IgG2a, IFN-γ and higher IL-10 attempting to reduce the NPs induced inflammatory effect).
The comparison between PMMA/DODAB NPs and DODAB bilayer fragments (BF) regarding the DTH response measured as footpad swelling (FS) also showed the mild inflammatory effect of the PMMA/DODAB NPs (FS = 0.70 mm) in comparison to DODAB BF (FS = 1.3).
Figure 8 shows schematically four different cationic nanostructures and their immune responses as studied in our group over the last 25 years.

4. Conclusions

PMMA/DODAB NPs with nanometric sizes, high zeta-potential and narrow size distribution were obtained by emulsion polymerization of MMA in the presence of DODAB (at 0.3 M MMA and 2.0 mM DODAB). From DODAB films for NPs synthesis sizes were always larger than the ones for NPs obtained from DODAB BF. PMMA/DODAB NPs exhibited functional behavior as immunoadjuvants. They were non cytotoxic against macrophages and fibroblasts in culture, combined well with OVA, as model antigen, were nanometric, showing high zeta-potential, low polydispersity and high colloidal stability in water dispersions. NPs/OVA induced high production of OVA-specific IgG1 and IgG2a in immunized mice, high delayed type hypersensitivity reaction, high production of IFN-γ, regulatory cytokine IL-10, IL-2 and IL-4. Quantitative determination of IgG1 and IgG2a titers reconfirmed the induction of a mixed Th1-Th2 response induced by the PMMA/DODAB/OVA NPs. In summary, there was enhanced humoral and cellular responses against OVA carried by the novel biocompatible adjuvant.

Author Contributions

Conceptualization, A.M.C.-R., E.L.F.-M. and Y.P.-B.; methodology, Y.P.-B., B.d.C.L.F.T., E.L.F.-M., P.M.A., D.R.P. and A.M.C.-R.; validation, A.M.C.-R., E.L.F.-M. and Y.P.-B.; formal analysis, A.M.C.-R., E.L.F.-M. and Y.P.-B.; investigation, Y.P.-B., B.d.C.L.F.T., E.L.F.-M., P.M.A., D.R.P. and A.M.C.-R.; resources, A.M.C.-R. and E.L.F.-M.; data curation, A.M.C.-R.; writing—original draft preparation, A.M.C.-R. and Y.P.-B.; writing—review and editing, A.M.C.-R. and Y.P.-B.; supervision, A.M.C.-R.; project administration, A.M.C.-R.; funding acquisition, A.M.C.-R. and E.L.F.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) by grants 302758/2019-4, 302352/2014-7 to A.M.C.-R.; 140091/2019-0 to Y.P.-B.; 312096/2018-6 to E.L.F.-M.) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) by grant 2019/17685-2 to A.M.C.-R and grant FAPESP 2019/17625-0 to E.L.F.-M. Y.P.-B. is the recipient of a CNPq Ph.D. fellowship (140091/2019-0) under A.M.C.-R. supervision for developing the project “Cationic Nanostructures for Vaccines”.

Institutional Review Board Statement

The study was approved by the Ethics Committee of Butantan Institute (protocol code 7912280219, April 2019).

Informed Consent Statement

Not applicable.

Data Availability Statement

All data available are reported in the article.

Acknowledgments

Y.P.-B. thanks CNPq for awarding a Ph.D. fellowship (140091/2019-0). P.M.A. was the recipient of an undergraduate fellowship from the Programa Institucional de Bolsas de Iniciação Científica (PIBIC)-CNPq grant 139161/2020-1. D.R.P. thanks to Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for granting a MSc fellowship (88887.467008/2019-00).

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Manolova, V.; Flace, A.; Bauer, M.; Schwarz, K.; Saudan, P.; Bachmann, M.F. Nanoparticles Target Distinct Dendritic Cell Populations According to Their Size. Eur. J. Immunol. 2008, 38, 1404–1413. [Google Scholar] [CrossRef]
  2. Fifis, T.; Gamvrellis, A.; Crimeen-Irwin, B.; Pietersz, G.A.; Li, J.; Mottram, P.L.; McKenzie, I.F.C.; Plebanski, M. Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors. J. Immunol. 2004, 173, 3148–3154. [Google Scholar] [CrossRef] [Green Version]
  3. Xiang, S.D.; Scholzen, A.; Minigo, G.; David, C.; Apostolopoulos, V.; Mottram, P.L.; Plebanski, M. Pathogen Recognition and Development of Particulate Vaccines: Does Size Matter? Methods 2006, 40, 1–9. [Google Scholar] [CrossRef]
  4. Carmona-Ribeiro, A.M. Cationic nanostructures for vaccines. In Immune Response Activation; Duc, G.H.T., Ed.; IntechOpen: Rijeka, Croatia, 2014; pp. 1–45. ISBN 978-953-51-1374-4. [Google Scholar]
  5. Carmona-Ribeiro, A.M. Chapter Thirteen—Nanomaterials Based on Lipids for Vaccine Development. In Micro and Nanotechnology in Vaccine Development; Skwarczynski, M., Toth, I., Eds.; Micro and Nano Technologies; William Andrew Publishing: Norwich, NY, USA, 2017; pp. 241–257. ISBN 978-0-323-39981-4. [Google Scholar]
  6. Mao, L.; Chen, Z.; Wang, Y.; Chen, C. Design and Application of Nanoparticles as Vaccine Adjuvants against Human Corona Virus Infection. J. Inorg. Biochem. 2021, 219, 111454. [Google Scholar] [CrossRef] [PubMed]
  7. Tsuruta, L.R.; Quintilio, W.; Costa, M.H.; Carmona-Ribeiro, A.M. Interactions between Cationic Liposomes and an Antigenic Protein: The Physical Chemistry of the Immunoadjuvant Action. J. Lipid Res. 1997, 38, 2003–2011. [Google Scholar] [CrossRef]
  8. Carmona-Ribeiro, A.M. Synthetic Amphiphile Vesicles. Chem. Soc. Rev. 1992, 21, 209–214. [Google Scholar] [CrossRef]
  9. Carmona-Ribeiro, A.M. Lipid Bilayer Fragments and Disks in Drug Delivery. Curr. Med. Chem. 2006, 13, 1359–1370. [Google Scholar] [CrossRef]
  10. Lincopan, N.; Espíndola, N.M.; Vaz, A.J.; da Costa, M.H.B.; Faquim-Mauro, E.; Carmona-Ribeiro, A.M. Novel Immunoadjuvants Based on Cationic Lipid: Preparation, Characterization and Activity In Vivo. Vaccine 2009, 27, 5760–5771. [Google Scholar] [CrossRef]
  11. Rozenfeld, J.H.K.; Silva, S.R.; Raneia, P.A.; Faquim-Mauro, E.; Carmona-Ribeiro, A.M. Stable Assemblies of Cationic Bilayer Fragments and CpG Oligonucleotide with Enhanced Immunoadjuvant Activity In Vivo. J. Control. Release Off. J. Control. Release Soc. 2012, 160, 367–373. [Google Scholar] [CrossRef]
  12. De Almeida, A.F.; De Gaspari, E. Dioctadecyldimethylammonium Bromide (DODAB-BF) as a New Adjuvant for Maternal-Fetal Immunization in Mice against Neisseria Meningitidis: Evaluation of Humoral Response. Pathog. Dis. 2018, 76, ftx128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Andersson, M.; Hammarstroem, L.; Edwards, K. Effect of Bilayer Phase Transitions on Vesicle Structure, and Its Influence on the Kinetics of Viologen Reduction. J. Phys. Chem. 1995, 99, 14531–14538. [Google Scholar] [CrossRef]
  14. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef] [PubMed]
  15. Lincopan, N.; Espindola, N.M.; Vaz, A.J.; Carmona-Ribeiro, A.M. Cationic Supported Lipid Bilayers for Antigen Presentation. Int. J. Pharm. 2007, 340, 216–222. [Google Scholar] [CrossRef]
  16. Naves, A.F.; Palombo, R.R.; Carrasco, L.D.M.; Carmona-Ribeiro, A.M. Antimicrobial Particles from Emulsion Polymerization of Methyl Methacrylate in the Presence of Quaternary Ammonium Surfactants. Langmuir 2013, 29, 9677–9684. [Google Scholar] [CrossRef] [PubMed]
  17. Sanches, L.M.; Petri, D.F.S.; de Melo Carrasco, L.D.; Carmona-Ribeiro, A.M. The Antimicrobial Activity of Free and Immobilized Poly(Diallyldimethylammonium) Chloride in Nanoparticles of Poly(Methylmethacrylate). J. Nanobiotechnol. 2015, 13, 58. [Google Scholar] [CrossRef] [Green Version]
  18. Xavier, G.R.S.; Carmona-Ribeiro, A.M. Cationic Biomimetic Particles of Polystyrene/Cationic Bilayer/Gramicidin for Optimal Bactericidal Activity. Nanomaterials 2017, 7, 422. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Mathiazzi, B.I.; Carmona-Ribeiro, A.M. Hybrid Nanoparticles of Poly(Methyl Methacrylate) and Antimicrobial Quaternary Ammonium Surfactants. Pharmaceutics 2020, 12, 340. [Google Scholar] [CrossRef]
  20. Carmona-Ribeiro, A.M.; Pérez-Betancourt, Y. Cationic Nanostructures for Vaccines Design. Biomimetics 2020, 5, 32. [Google Scholar] [CrossRef]
  21. Pérez-Betancourt, Y.; Távora, B.d.C.L.F.; Faquim-Mauro, E.L.; Carmona-Ribeiro, A.M. Biocompatible Lipid Polymer Cationic Nanoparticles for Antigen Presentation. Polymers 2021, 13, 185. [Google Scholar] [CrossRef]
  22. Ribeiro, A.M.; Chaimovich, H. Preparation and Characterization of Large Dioctadecyldimethylammonium Chloride Liposomes and Comparison with Small Sonicated Vesicles. Biochim. Biophys. Acta 1983, 733, 172–179. [Google Scholar] [CrossRef]
  23. Carmona-Ribeiro, A.M.; Chaimovich, H. Salt-Induced Aggregation and Fusion of Dioctadecyldimethylammonium Chloride and Sodium Dihexadecylphosphate Vesicles. Biophys. J. 1986, 50, 621–628. [Google Scholar] [CrossRef] [Green Version]
  24. Carvalho, L.A.; Carmona-Ribeiro, A.M. Interactions between Cationic Vesicles and Serum Proteins. Langmuir 1998, 14, 6077–6081. [Google Scholar] [CrossRef]
  25. Lincopan, N.; Carmona-Ribeiro, A.M. Protein Assembly onto Cationic Supported Bilayers. J. Nanosci. Nanotechnol. 2009, 9, 3578–3586. [Google Scholar] [CrossRef] [PubMed]
  26. Carvalho, C.A.; Olivares-Ortega, C.; Soto-Arriaza, M.A.; Carmona-Ribeiro, A.M. Interaction of Gramicidin with DPPC/DODAB Bilayer Fragments. Biochim. Biophys. Acta 2012, 1818, 3064–3071. [Google Scholar] [CrossRef] [PubMed]
  27. Ragioto, D.A.M.T.; Carrasco, L.D.M.; Carmona-Ribeiro, A.M. Novel Gramicidin Formulations in Cationic Lipid as Broad-Spectrum Microbicidal Agents. Int. J. Nanomed. 2014, 9, 3183–3192. [Google Scholar] [CrossRef] [Green Version]
  28. Rozenfeld, J.H.K.; Oliveira, T.R.; Lamy, M.T.; Carmona-Ribeiro, A.M. Interaction of Cationic Bilayer Fragments with a Model Oligonucleotide. Biochim. Biophys. Acta 2011, 1808, 649–655. [Google Scholar] [CrossRef] [PubMed]
  29. Kikuchi, I.S.; Viviani, W.; Carmona-Ribeiro, A.M. Nucleotide Insertion in Cationic Bilayers. J. Phys. Chem. A 1999, 103, 8050–8055. [Google Scholar] [CrossRef]
  30. Nantes, I.L.; Correia, F.M.; Faljoni-Alario, A.; Kawanami, A.E.; Ishiki, H.M.; Amaral, A.T.; Carmona-Ribeiro, A.M. Nucleotide Conformational Change Induced by Cationic Bilayers. Arch. Biochem. Biophys. 2003, 416, 25–30. [Google Scholar] [CrossRef]
  31. Rosa, H.; Petri, D.F.S.; Carmona-Ribeiro, A.M. Interactions between Bacteriophage DNA and Cationic Biomimetic Particles. J. Phys. Chem. B 2008, 112, 16422–16430. [Google Scholar] [CrossRef]
  32. Kikuchi, I.S.; Carmona-Ribeiro, A.M. Interactions between DNA and Synthetic Cationic Liposomes. J. Phys. Chem. B 2000, 104, 2829–2835. [Google Scholar] [CrossRef]
  33. Carmona-Ribeiro, A.M.; Midmore, B.R. Synthetic Bilayer Adsorption onto Polystyrene Microspheres. Langmuir 1992, 8, 801–806. [Google Scholar] [CrossRef]
  34. Carmona-Ribeiro, A.M.; de Moraes Lessa, M. Interactions between Bilayer Membranes and Latex. Colloids Surf. A Physicochem. Eng. Asp. 1999, 153, 355–361. [Google Scholar] [CrossRef]
  35. Pereira, E.M.A.; Vieira, D.B.; Carmona-Ribeiro, A.M. Cationic Bilayers on Polymeric Particles: Effect of Low NaCl Concentration on Surface Coverage. J. Phys. Chem. B 2004, 108, 11490–11495. [Google Scholar] [CrossRef]
  36. Rapuano, R.; Carmona-Ribeiro, A.M. Supported Bilayers on Silica. J. Colloid Interface Sci. 2000, 226, 299–307. [Google Scholar] [CrossRef]
  37. Moura, S.P.; Carmona-Ribeiro, A.M. Cationic Bilayer Fragments on Silica at Low Ionic Strength: Competitive Adsorption and Colloid Stability. Langmuir 2003, 19, 6664–6667. [Google Scholar] [CrossRef]
  38. Lincopan, N.; Santana, M.R.; Faquim-Mauro, E.; da Costa, M.H.B.; Carmona-Ribeiro, A.M. Silica-Based Cationic Bilayers as Immunoadjuvants. BMC Biotechnol. 2009, 9, 5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Ribeiro, R.T.; Braga, V.H.A.; Carmona-Ribeiro, A.M. Biomimetic Cationic Nanoparticles Based on Silica: Optimizing Bilayer Deposition from Lipid Films. Biomimetics 2017, 2, 20. [Google Scholar] [CrossRef]
  40. Pereira, E.M.A.; Kosaka, P.M.; Rosa, H.; Vieira, D.B.; Kawano, Y.; Petri, D.F.S.; Carmona-Ribeiro, A.M. Hybrid Materials from Intermolecular Associations between Cationic Lipid and Polymers. J. Phys. Chem. B 2008, 112, 9301–9310. [Google Scholar] [CrossRef]
  41. Sobral, C.N.C.; Soto, M.A.; Carmona-Ribeiro, A.M. Characterization of DODAB/DPPC Vesicles. Chem. Phys. Lipids 2008, 152, 38–45. [Google Scholar] [CrossRef] [PubMed]
  42. Carmona-Ribeiro, A.M. Self-Assembled Antimicrobial Nanomaterials. Int. J. Environ. Res. Public Health 2018, 15, 1408. [Google Scholar] [CrossRef] [Green Version]
  43. Galvão, C.N.; Sanches, L.M.; Mathiazzi, B.I.; Ribeiro, R.T.; Petri, D.F.S.; Carmona-Ribeiro, A.M. Antimicrobial Coatings from Hybrid Nanoparticles of Biocompatible and Antimicrobial Polymers. Int. J. Mol. Sci. 2018, 19, 2965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Grabowski, E.; Morrison, I. Particle size distribution from analysis of quasi-elastic light-scattering data. In Measurement of Suspended Particles by Quasi-Elastic Light-Scattering; Dahneke, B., Ed.; Wiley Interscience: New York, NY, USA, 1983; pp. 199–236. ISBN 0-471-87289-X. [Google Scholar]
  45. Ribeiro, R.T.; Galvão, C.N.; Betancourt, Y.P.; Mathiazzi, B.I.; Carmona-Ribeiro, A.M. Microbicidal Dispersions and Coatings from Hybrid Nanoparticles of Poly(Methyl Methacrylate), Poly(Diallyl Dimethyl Ammonium) Chloride, Lipids, and Surfactants. Int. J. Mol. Sci. 2019, 20, 6150. [Google Scholar] [CrossRef] [Green Version]
  46. Schales, O.; Schales, S.S. A Simple and Accurate Method for the Determination of Chloride in Biological Fluids. J. Biol. Chem. 1941, 140, 879–882. [Google Scholar] [CrossRef]
  47. Walker, J.M. The Bicinchoninic Acid (BCA) Assay for Protein Quantitation. Methods Mol. Biol. 1994, 32, 5–8. [Google Scholar] [CrossRef]
  48. Hilgers, L.A.; Snippe, H. DDA as an Immunological Adjuvant. Res. Immunol. 1992, 143, 494–503; discussion 574–576. [Google Scholar] [CrossRef]
  49. Lage, R.S.; Oliveira, G.C.; Busek, S.U.; Guerra, L.L.; Giunchetti, R.C.; Corrêa-Oliveira, R.; Reis, A.B. Analysis of the Cytokine Profile in Spleen Cells from Dogs Naturally Infected by Leishmania Chagasi. Vet. Immunol. Immunopathol. 2007, 115, 135–145. [Google Scholar] [CrossRef] [PubMed]
  50. Patra, C.N.; Priya, R.; Swain, S.; Kumar Jena, G.; Panigrahi, K.C.; Ghose, D. Pharmaceutical Significance of Eudragit: A Review. Future J. Pharm. Sci. 2017, 3, 33–45. [Google Scholar] [CrossRef]
  51. Carmona-Ribeiro, A.M.; Araújo, P.M. Antimicrobial Polymer-Based Assemblies: A Review. Int. J. Mol. Sci. 2021, 22, 5424. [Google Scholar] [CrossRef] [PubMed]
  52. Martins, L.M.S.; Mamizuka, E.M.; Carmona-Ribeiro, A.M. Cationic Vesicles as Bactericides. Langmuir 1997, 13, 5583–5587. [Google Scholar] [CrossRef]
  53. Sicchierolli, S.M.; Mamizuka, E.M.; Carmona-Ribeiro, A.M. Bacteria Flocculation and Death by Cationic Vesicles. Langmuir 1995, 11, 2991–2995. [Google Scholar] [CrossRef]
  54. Tapias, G.N.; Sicchierolli, S.M.; Mamizuka, E.M.; Carmona-Ribeiro, A.M. Interactions between Cationic Vesicles and Escherichia coli. Langmuir 1994, 10, 3461–3465. [Google Scholar] [CrossRef]
  55. Campanhã, M.T.; Mamizuka, E.M.; Carmona-Ribeiro, A.M. Interactions between Cationic Liposomes and Bacteria: The Physical-Chemistry of the Bactericidal Action. J. Lipid Res. 1999, 40, 1495–1500. [Google Scholar] [CrossRef]
  56. Carmona-Ribeiro, A.M.; Midmore, B.R. Surface Potential in Charged Synthetic Amphiphile Vesicles. J. Phys. Chem. 1992, 96, 3542–3547. [Google Scholar] [CrossRef]
  57. Melo, L.D.; Palombo, R.R.; Petri, D.F.S.; Bruns, M.; Pereira, E.M.A.; Carmona-Ribeiro, A.M. Structure–Activity Relationship for Quaternary Ammonium Compounds Hybridized with Poly(Methyl Methacrylate). ACS Appl. Mater. Interfaces 2011, 3, 1933–1939. [Google Scholar] [CrossRef] [PubMed]
  58. Rapuano, R.; Carmona-Ribeiro, A.M. Physical Adsorption of Bilayer Membranes on Silica. J. Colloid Interface Sci. 1997, 193, 104–111. [Google Scholar] [CrossRef] [PubMed]
  59. Carmona-Ribeiro, A.M.; Ortis, F.; Schumacher, R.I.; Armelin, M.C.S. Interactions between Cationic Vesicles and Cultured Mammalian Cells. Langmuir 1997, 13, 2215–2218. [Google Scholar] [CrossRef]
  60. Perez-Betancourt, Y.; de Carvalho Lins Fernandes Távora, B.; Colombini, M.; Faquim-Mauro, E.L.; Carmona-Ribeiro, A.M. Simple Nanoparticles from the Assembly of Cationic Polymer and Antigen as Immunoadjuvants. Vaccines 2020, 8, 105. [Google Scholar] [CrossRef] [Green Version]
  61. Gan, L.M.; Chew, C.H.; Ng, S.C.; Loh, S.E. Polymerization of Methyl Methacrylate in Ternary Systems: Emulsion and Microemulsion. Langmuir 1993, 9, 2799–2803. [Google Scholar] [CrossRef]
  62. Arif, U.; Haider, S.; Haider, A.; Khan, N.; Alghyamah, A.A.; Jamila, N.; Khan, M.I.; Almasry, W.A.; Kang, I.-K. Biocompatible Polymers and Their Potential Biomedical Applications: A Review. Curr. Pharm. Des. 2019, 25, 3608–3619. [Google Scholar] [CrossRef]
  63. Webster, O.W. Group Transfer Polymerization: A Critical Review of Its Mechanism and Comparison with Other Methods for Controlled Polymerization of Acrylic Monomers. In New Synthetic Methods; Springer: Berlin/Heidelberg, Germany, 2004; pp. 1–34. ISBN 978-3-540-36458-0. [Google Scholar]
  64. Xu, L.; Liu, Y.; Chen, Z.; Li, W.; Liu, Y.; Wang, L.; Liu, Y.; Wu, X.; Ji, Y.; Zhao, Y.; et al. Surface-Engineered Gold Nanorods: Promising DNA Vaccine Adjuvant for HIV-1 Treatment. Nano Lett. 2012, 12, 2003–2012. [Google Scholar] [CrossRef]
Pharmaceutics 13 01859 sch001 550
Scheme 1. Chemical structures of dimethyl dioctadecyl ammonium bromide (DODAB), methyl methacrylate (MMA) and polymethyl methacrylate (PMMA).
Scheme 1. Chemical structures of dimethyl dioctadecyl ammonium bromide (DODAB), methyl methacrylate (MMA) and polymethyl methacrylate (PMMA).
Pharmaceutics 13 01859 sch001
Pharmaceutics 13 01859 g001 550
Figure 1. Effect of methyl methacrylate (MMA) concentration (a–c) or dioctadecyl dimethyl ammonium bromide (DODAB) concentration on main characteristics of PMMA/DODAB NPs synthesized by emulsion polymerization of MMA in the presence of DODAB (d–f). From dynamic light scattering (DLS), mean hydrodynamic diameter (Dz) (a,d), zeta—potential (ζ) (b,e) and polydispersity (P) (c,f) were determined for the dispersions in pure water. NPs in dispersion at 1.5 mM DODAB were synthesized over a range of [MMA]. NPs were also synthesized at 0.3 M MMA over a range of [DODAB].
Figure 1. Effect of methyl methacrylate (MMA) concentration (a–c) or dioctadecyl dimethyl ammonium bromide (DODAB) concentration on main characteristics of PMMA/DODAB NPs synthesized by emulsion polymerization of MMA in the presence of DODAB (d–f). From dynamic light scattering (DLS), mean hydrodynamic diameter (Dz) (a,d), zeta—potential (ζ) (b,e) and polydispersity (P) (c,f) were determined for the dispersions in pure water. NPs in dispersion at 1.5 mM DODAB were synthesized over a range of [MMA]. NPs were also synthesized at 0.3 M MMA over a range of [DODAB].
Pharmaceutics 13 01859 g001
Pharmaceutics 13 01859 g002 550
Figure 2. Incorporation of dioctadecyl dimethyl ammonium bromide (DODAB) in in poly(methyl methacrylate) (PMMA)/DODAB nanoparticles (NPs) as a function of methyl methacrylate concentration ([MMA]) using 1.5 mM DODAB (a) and as a function of DODAB concentration employing 0.3 M MMA (b).
Figure 2. Incorporation of dioctadecyl dimethyl ammonium bromide (DODAB) in in poly(methyl methacrylate) (PMMA)/DODAB nanoparticles (NPs) as a function of methyl methacrylate concentration ([MMA]) using 1.5 mM DODAB (a) and as a function of DODAB concentration employing 0.3 M MMA (b).
Pharmaceutics 13 01859 g002
Pharmaceutics 13 01859 g003 550
Figure 3. Cell viability of macrophages (J774A.1) or fibroblasts (L929) as affected by three different adjuvants containing dioctadecyl dimethyl ammonium bromide (DODAB) at 3 (a,c) and 24 h interaction time (b,d). The adjuvants were DODAB bilayer fragments (DODAB BF) (in yellow), DODAB bilayer vesicles (DODAB LV) (in blue) and poly (methyl methacrylate) (PMMA)/DODAB hybrid NPs (in gray). The DODAB concentration used for the three different adjuvants (PMMA/DODAB NPs, DODAB BF and DODAB LV) was indicated by the red arrow and corresponded to 0.08 mM DODAB.
Figure 3. Cell viability of macrophages (J774A.1) or fibroblasts (L929) as affected by three different adjuvants containing dioctadecyl dimethyl ammonium bromide (DODAB) at 3 (a,c) and 24 h interaction time (b,d). The adjuvants were DODAB bilayer fragments (DODAB BF) (in yellow), DODAB bilayer vesicles (DODAB LV) (in blue) and poly (methyl methacrylate) (PMMA)/DODAB hybrid NPs (in gray). The DODAB concentration used for the three different adjuvants (PMMA/DODAB NPs, DODAB BF and DODAB LV) was indicated by the red arrow and corresponded to 0.08 mM DODAB.
Pharmaceutics 13 01859 g003
Pharmaceutics 13 01859 g004 550
Figure 4. Poly(methyl methacrylate)/dioctadecyl dimethyl ammonium bromide (PMMA/DODAB) NPs at 0.5 mg/mL PMMA over a range of ovalbumin (OVA) concentrations: (a) photos of the dispersions; (b) OVA adsorption on NPs as a function of added OVA; (c) mean hydrodynamic diameter (Dz); (d) zeta-potential (ζ); (e) polydispersity of the dispersions (P). The stock solution of OVA used was 10 mg/mL whereas the red dot indicates properties of dispersions obtained from a 1 mg/mL OVA stock solution. The immunology tests were performed using the last stock solution of OVA. The red rectangle corresponds to the OVA concentration region of poor colloidal stability, meaning that DLS measurments could not be performed due to precipitation in the tubes.
Figure 4. Poly(methyl methacrylate)/dioctadecyl dimethyl ammonium bromide (PMMA/DODAB) NPs at 0.5 mg/mL PMMA over a range of ovalbumin (OVA) concentrations: (a) photos of the dispersions; (b) OVA adsorption on NPs as a function of added OVA; (c) mean hydrodynamic diameter (Dz); (d) zeta-potential (ζ); (e) polydispersity of the dispersions (P). The stock solution of OVA used was 10 mg/mL whereas the red dot indicates properties of dispersions obtained from a 1 mg/mL OVA stock solution. The immunology tests were performed using the last stock solution of OVA. The red rectangle corresponds to the OVA concentration region of poor colloidal stability, meaning that DLS measurments could not be performed due to precipitation in the tubes.
Pharmaceutics 13 01859 g004
Pharmaceutics 13 01859 g005 550
Figure 5. Antibody production in sera on days 14, 21 and 28 after immunization as induced by ovalbumin (OVA), Al(OH)3/OVA and NPs/OVA. The mean absorbance measured at 492 nm ± standard deviation was relative to the production of OVA-specific IgG1 (a) or IgG2a (b). Serum dilution to present IgG1 primary response was 1/1024 and IgG2a primary response was showed at 1/32. Secondary response of IgG1 was displayed at 1/512,000 whereas IgG2a secondary response was presented at 1/512. p < 0.05 compared to the naive group (#), p < 0.05 compared to the OVA group (*), p < 0.05 compared to the Al(OH)3/OVA group (∆).
Figure 5. Antibody production in sera on days 14, 21 and 28 after immunization as induced by ovalbumin (OVA), Al(OH)3/OVA and NPs/OVA. The mean absorbance measured at 492 nm ± standard deviation was relative to the production of OVA-specific IgG1 (a) or IgG2a (b). Serum dilution to present IgG1 primary response was 1/1024 and IgG2a primary response was showed at 1/32. Secondary response of IgG1 was displayed at 1/512,000 whereas IgG2a secondary response was presented at 1/512. p < 0.05 compared to the naive group (#), p < 0.05 compared to the OVA group (*), p < 0.05 compared to the Al(OH)3/OVA group (∆).
Pharmaceutics 13 01859 g005
Pharmaceutics 13 01859 g006 550
Figure 6. Delayed-type hypersensitivity reaction assessed as the mean footpad swelling ± standard deviation of animals immunized with ovalbumin (OVA), Al(OH)3/OVA or PMMA/DODAB/OVA (NP/OVA). p < 0.05 compared to the naive group (*), p < 0.05 compared to the OVA group (#), p < 0.05 compared to the Al(OH)3/OVA group (∆).
Figure 6. Delayed-type hypersensitivity reaction assessed as the mean footpad swelling ± standard deviation of animals immunized with ovalbumin (OVA), Al(OH)3/OVA or PMMA/DODAB/OVA (NP/OVA). p < 0.05 compared to the naive group (*), p < 0.05 compared to the OVA group (#), p < 0.05 compared to the Al(OH)3/OVA group (∆).
Pharmaceutics 13 01859 g006
Pharmaceutics 13 01859 g007 550
Figure 7. Production IL-4 (a), IL-10 (b), IL-2 (c) and IFN-γ (d) (pg/mL) elicited by cultured spleen cells obtained from naïve or animals immunized with ovalbumin (OVA), Al(OH)3/OVA, PMMA/DODAB/OVA (NPs/OVA). p < 0.05 compared to the naive group (•), p < 0.05 compared to the OVA group (#), p < 0.05 compared to the Al(OH)3/OVA group (∆). Splenocytes were challenged with OVA, medium (negative control) and concanavalin-A (Con-A) (positive control).
Figure 7. Production IL-4 (a), IL-10 (b), IL-2 (c) and IFN-γ (d) (pg/mL) elicited by cultured spleen cells obtained from naïve or animals immunized with ovalbumin (OVA), Al(OH)3/OVA, PMMA/DODAB/OVA (NPs/OVA). p < 0.05 compared to the naive group (•), p < 0.05 compared to the OVA group (#), p < 0.05 compared to the Al(OH)3/OVA group (∆). Splenocytes were challenged with OVA, medium (negative control) and concanavalin-A (Con-A) (positive control).
Pharmaceutics 13 01859 g007
Pharmaceutics 13 01859 g008 550
Figure 8. Cationic nanostructures from biocompatible polymer and cationic lipid and/or cationic polymer.
Figure 8. Cationic nanostructures from biocompatible polymer and cationic lipid and/or cationic polymer.
Pharmaceutics 13 01859 g008
Table
Table 1. Solutions or dispersions in pure water used in mice immunization.
Table 1. Solutions or dispersions in pure water used in mice immunization.
GroupSolution/
Dispersion		OVA
mg/mL		Al(OH)3
mg/mL		PMMA
mg/mL		DODAB
mM
1Ultrapure water0000
2Ovalbumin (OVA)0.05000
3Al(OH)3/OVA0.050.1000
4PMMA/DODAB/OVA0.0500.500.08 1
1 0.08 mM DODAB is equivalent to 0.05 mg/mL.
Table
Table 2. Endpoint titer of OVA-specific IgG1, IgG2a and IgG1/IgG2a ratio determined 21 days after immunization.
Table 2. Endpoint titer of OVA-specific IgG1, IgG2a and IgG1/IgG2a ratio determined 21 days after immunization.
GroupIgG1IgG2aIgG1/IgG2a
OVA1434 ± 36014 ± 10102
Al(OH)3/OVA35,200 ± 13,00058 ± 14607
NPs/OVA41,600 ± 15,648358 ± 132116
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Pérez-Betancourt, Y.; Araujo, P.M.; Távora, B.d.C.L.F.; Pereira, D.R.; Faquim-Mauro, E.L.; Carmona-Ribeiro, A.M. Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants. Pharmaceutics 2021, 13, 1859. https://doi.org/10.3390/pharmaceutics13111859

AMA Style

Pérez-Betancourt Y, Araujo PM, Távora BdCLF, Pereira DR, Faquim-Mauro EL, Carmona-Ribeiro AM. Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants. Pharmaceutics. 2021; 13(11):1859. https://doi.org/10.3390/pharmaceutics13111859

Chicago/Turabian Style

Pérez-Betancourt, Yunys, Péricles Marques Araujo, Bianca de Carvalho Lins Fernandes Távora, Daniele Rodrigues Pereira, Eliana Lima Faquim-Mauro, and Ana Maria Carmona-Ribeiro. 2021. "Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants" Pharmaceutics 13, no. 11: 1859. https://doi.org/10.3390/pharmaceutics13111859

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop